The Microbiome Therapeutics Innovation Group (MTIG) announced the addition of Bacthera to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs.

Bacthera is a specialized contract development and manufacturing organization (CDMO) that offers services across the Live Biotherapeutics Products (LBP) life cycle and process chain, from technical R&D development to GMP manufacture and QC testing of drug substance and drug product.

Chairman of MTIG & CEO of Siolta Therapeutics, Nikole Kimes, Ph.D., said: “We are excited to welcome Bacthera as the newest MTIG member and the first CDMO to join our coalition. We believe the manufacturing of LBPs is a key component to the growth of the microbiome therapeutics industry as a whole and look forward to working alongside Bacthera and utilizing its world-class industry expertise to help pursue our goal of building tangible policy and regulatory solutions that support the emerging microbiome arena.”

Bacthera CEO, Lukas Schüpbach said: “Bacthera is honored to join the Microbiome Therapeutics Innovation Group. We look forward to working with Nikole and the entire coalition in advancing MTIG’s mission to accelerate microbiome therapeutic product development & manufacturing and expanding the availability of life-changing and life-saving FDA approved microbiome therapies to doctors and patients.”